Literature DB >> 8623459

Prolonged immunosuppressive effect and minimal immunogenicity from chimeric (CD25) monoclonal antibody SDZ CHI 621 in renal transplantation.

J M Kovarik1, E Rawlings, P Sweny, O Fernando, R Moore, P J Griffin, P Fauchald, D Albrechtsen, G Sodal, K Nordal, P L Amlot.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8623459

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  5 in total

Review 1.  Therapeutic drug monitoring of immunosuppressant drugs.

Authors:  A Johnston; D W Holt
Journal:  Br J Clin Pharmacol       Date:  1999-04       Impact factor: 4.335

Review 2.  Basiliximab.

Authors:  S V Onrust; L R Wiseman
Journal:  Drugs       Date:  1999-02       Impact factor: 9.546

Review 3.  Basiliximab: a review of its use as induction therapy in renal transplantation.

Authors:  Therese M Chapman; Gillian M Keating
Journal:  Drugs       Date:  2003       Impact factor: 9.546

4.  Comparative in vitro study of the immunomodulatory activity of humanized and chimeric anti-CD25 monoclonal antibodies.

Authors:  B Kircher; K Lätzer; G Gastl; D Nachbaur
Journal:  Clin Exp Immunol       Date:  2003-12       Impact factor: 4.330

5.  Immune Reconstitution of Patients Who Recovered From Steroid-Refractory Acute Graft-Versus-Host Disease After Basiliximab Treatment.

Authors:  Dao-Xing Deng; Shuang Fan; Xiao-Hui Zhang; Lan-Ping Xu; Yu Wang; Chen-Hua Yan; Huan Chen; Yu-Hong Chen; Wei Han; Feng-Rong Wang; Jing-Zhi Wang; Xu-Ying Pei; Ying-Jun Chang; Kai-Yan Liu; Xiao-Jun Huang; Xiao-Dong Mo
Journal:  Front Oncol       Date:  2022-07-15       Impact factor: 5.738
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.